Stephen E. Sallan , MD

	Chief of Staff, Dana-Farber Cancer Institute Office Phone: 617-632-3316 Appointment Line: 1-888-PEDI-ONC (733-4662) Fax: 617-632-5511 Email this provider NPI: 1467421800

Chief of Staff, Dana-Farber Cancer Institute

Office Phone: 617-632-3316

Appointment Line: 1-888-PEDI-ONC (733-4662)

Fax: 617-632-5511

NPI: 1467421800

acute lymphoblastic leukemia (ALL)

hematology/oncology

Professor of Pediatrics, Harvard Medical School

Pediatrics

Wayne State University School of Medicine, Detroit, MI (1967)

New England Medical Center, Boston, MA (07/67 to 06/68)

Children's Hospital of Philadelphia, Philadelphia, PA (7/68 to 6/69)

Hospital for Sick Children, London, England (7/69 to 6/70)

Pediatric Hematology/Oncology, Children's Hospital Boston/Dana-Farber Cancer Institute, Boston, MA (7/72 to 6/75)

Boston Magazine Top Doctors 2011 , December 2011

Boston Magazine

Research site for Stephen Sallan, MD

Acute Lymphoblastic Leukemia

Biology, complications and therapy of acute lymphoblastic leukemia (N Engl J Med 332:1738, 1995; Blood 97:1211, 2001; J Clin Oncol 19:1040, 2001; 20:237, 2002; 20:1677, 2002; 21: 2953, 2003; 21: 3616, 2003 and 22:2701, 2004; Blood 102: 4520, 2003; 103:3544, 2004 and 103:4602, 2004; Blood 106:1749, 2005; Blood 106:2484, 2005; Cancer Res 65:10050, 2005; Blood 107: 4508, 2006
Involvement of the TEL oncogene as a favorable risk factor in childhood ALL; detection, quantitation and prognostic implications of residual disease (Blood 88:4252, 1996; Blood 92:4792, 1998)
Adoptive T-cell therapy for ALL (Blood 94:3531, 1999; 98:533, 2001)
Prevention of anthracycline-induced cardiac injury (N Engl J Med 351:145, 2004; Pediatr 115:1613, 2005; J Clin Oncol 23:2629, 2005)
Targeting FLT3 in MLL- rearranged Leukemias (Blood 106:2484, 2005)